TY - JOUR
T1 - Future agents and treatment directions in multiple myeloma
AU - Ocio, Enrique M.
AU - Mitsiades, Constantine S.
AU - Orlowski, Robert Z.
AU - Anderson, Kenneth C.
PY - 2014/2
Y1 - 2014/2
N2 - The development of bortezomib and immunomodulatory agents resulted in a revolution in the treatment of multiple myeloma (MM). Moreover, second-generation proteasome inhibitors (carfilzomib) and immunomodulatory agents (pomalidomide) have recently been approved. Nevertheless, the incurability of this disease requires other drugs with different mechanisms of action to either prolong the survival of patients refractory to current therapies, or achieve cure. Active research has been done exploring the pathogenesis of MM and searching for novel, druggable targets. In this regard, some of these novel agents seem promising, such as monoclonal antibodies (anti-CD38-daratumumab or anti-CS1-elotuzumab) or the kinesin protein inhibitor Arry-520. Other agents under investigation are kinase inhibitors, signaling pathways inhibitors or deacetylase inhibitors. With so many novel agents under investigation, future therapy in MM will probably involve the combined use of the already approved drugs with some of those newly discovered.
AB - The development of bortezomib and immunomodulatory agents resulted in a revolution in the treatment of multiple myeloma (MM). Moreover, second-generation proteasome inhibitors (carfilzomib) and immunomodulatory agents (pomalidomide) have recently been approved. Nevertheless, the incurability of this disease requires other drugs with different mechanisms of action to either prolong the survival of patients refractory to current therapies, or achieve cure. Active research has been done exploring the pathogenesis of MM and searching for novel, druggable targets. In this regard, some of these novel agents seem promising, such as monoclonal antibodies (anti-CD38-daratumumab or anti-CS1-elotuzumab) or the kinesin protein inhibitor Arry-520. Other agents under investigation are kinase inhibitors, signaling pathways inhibitors or deacetylase inhibitors. With so many novel agents under investigation, future therapy in MM will probably involve the combined use of the already approved drugs with some of those newly discovered.
KW - immunomodulatory agents
KW - monoclonal antibodies
KW - multiple myeloma
KW - proteasome inhibitors
KW - targeted agents
KW - targeted drugs
UR - http://www.scopus.com/inward/record.url?scp=84893266741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893266741&partnerID=8YFLogxK
U2 - 10.1586/17474086.2014.858595
DO - 10.1586/17474086.2014.858595
M3 - Review article
C2 - 24350987
AN - SCOPUS:84893266741
SN - 1747-4086
VL - 7
SP - 127
EP - 141
JO - Expert review of hematology
JF - Expert review of hematology
IS - 1
ER -